Below are the most recent publications written about "Niacinamide" by people in Profiles.
-
Johns MS, Merritt WT, Rhodes L, Ford CN, Thompson M, Lee WM, Sheldon Y, Petrelli NJ, Tiesi GJ. A cost analysis of sorafenib for desmoid tumors. J Oncol Pharm Pract. 2023 Apr; 29(3):663-668.
-
Brose MS, Smit J, Lin CC, Pitoia F, Fellous M, DeSanctis Y, Schlumberger M, Tori M, Sugitani I. Timing of multikinase inhibitor initiation in differentiated thyroid cancer. Endocr Relat Cancer. 2017 05; 24(5):237-242.
-
Rouleau L, Antony AN, Bisetto S, Newberg A, Doria C, Levine M, Monti DA, Hoek JB. Synergistic effects of ascorbate and sorafenib in hepatocellular carcinoma: New insights into ascorbate cytotoxicity. Free Radic Biol Med. 2016 06; 95:308-322.
-
Yarchoan M, Ma C, Troxel AB, Stopenski SJ, Tang W, Cohen AB, Pappas-Paxinos M, Johnson BA, Chen EY, Feldman MD, Brose MS. pAKT Expression and Response to Sorafenib in Differentiated Thyroid Cancer. Horm Cancer. 2016 06; 7(3):188-95.
-
Worden F, Fassnacht M, Shi Y, Hadjieva T, Bonichon F, Gao M, Fugazzola L, Ando Y, Hasegawa Y, Park DJ, Shong YK, Smit JW, Chung J, Kappeler C, Meinhardt G, Schlumberger M, Brose MS. Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer. Endocr Relat Cancer. 2015 12; 22(6):877-87.
-
Brose MS, Schlumberger M, Pe?a C, Kappeler C. Sorafenib for patients with differentiated thyroid cancer--authors' reply. Lancet. 2015 Jan 17; 385(9964):228-9.
-
Wong P, Houghton P, Kirsch DG, Finkelstein SE, Monjazeb AM, Xu-Welliver M, Dicker AP, Ahmed M, Vikram B, Teicher BA, Coleman CN, Machtay M, Curran WJ, Wang D. Combining targeted agents with modern radiotherapy in soft tissue sarcomas. J Natl Cancer Inst. 2014 Nov; 106(11).
-
Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R, Shong YK, Sherman SI, Smit JW, Chung J, Kappeler C, Pe?a C, Moln?r I, Schlumberger MJ. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014 Jul 26; 384(9940):319-28.
-
Tobin GA, Zhang J, Goodwin D, Stewart S, Xu L, Knapton A, Gonz?lez C, Bancos S, Zhang L, Lawton MP, Enerson BE, Weaver JL. The role of eNOS phosphorylation in causing drug-induced vascular injury. Toxicol Pathol. 2014 Jun; 42(4):709-24.
-
Brose MS, Frenette CT, Keefe SM, Stein SM. Management of sorafenib-related adverse events: a clinician's perspective. Semin Oncol. 2014 Feb; 41 Suppl 2:S1-S16.